12 October 2021: Original Paper
Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
Chengxin Luo 12CDE , Qingrong Li 12B , Xi Li 3B , Guixian Wu 12B , Xiangtao Huang 12B , Yali Zhang 12B , Yanni Ma 12B , Mingling Xie 12B , Yanni Sun 12B , Yarui Huang 12B , Zhen Huang 12B , Shuangnian Xu 12AEG* , Jieping Chen 12AEG*DOI: 10.12659/AOT.933365
Ann Transplant 2021; 26:e933365
Table 1 Characteristics of included patients.
| Characteristic | Total | High albumin (≥37 g/L) | Low albumin (<37 g/L) | P |
|---|---|---|---|---|
| Gender | 0.409 | |||
| Male | 71 (62.8%) | 60 (61.2%) | 11 (73.3%) | |
| Female | 42 (37.2%) | 38 (38.8%) | 4 (26.7%) | |
| Age | 0.128 | |||
| >60 years | 10 (8.8%) | 7 (7.1%) | 3 (20.0%) | |
| ≤60 years | 103 (91.2%) | 91 (92.9%) | 12 (80.0%) | |
| BMI | 0.355 | |||
| 11 (10.1%) | 11 (11.7%) | 0 | ||
| ≥18.5 | 98 (89.9%) | 83 (88.3%) | 15 (100%) | |
| Disease | 0.316 | |||
| HL | 14 (12.4%) | 14 (14.3%) | 0 | |
| NHL | 99 (87.6%) | 84 (85.7%) | 15 (100%) | |
| B-NHL | 80 (70.8%) | 66 (78.6%) | 14 (93.3%) | |
| T-NHL | 15 (13.3%) | 14 (16.7%) | 1 (6.7%) | |
| NK/T-NHL | 4 (3.5%) | 4 (4.8%) | 0 | |
| ECOG PS | 0.575 | |||
| 0–1 | 69 (61.1%) | 61 (62.2%) | 8 (53.3%) | |
| 2–3 | 44 (38.9%) | 37 (37.8%) | 7 (46.7%) | |
| Ann Arbor stage | 0.732 | |||
| I–II | 22 (19.5%) | 20 (20.4%) | 2 (13.3%) | |
| III–IV | 91 (80.5%) | 78 (79.6%) | 13 (86.7%) | |
| B symptoms | 0.568 | |||
| Absent | 73 (64.6%) | 62 (63.3%) | 11 (73.3%) | |
| Present | 40 (35.4%) | 36 (36.7%) | 4 (26.7%) | |
| IPI risk | 0.117 | |||
| Low | 40 (35.4%) | 37 (37.8%) | 3 (20.0%) | |
| Low-intermediate | 36 (31.9%) | 32 (32.7%) | 4 (11.1%) | |
| High-intermediate | 22 (19.5%) | 19 (19.4%) | 3 (20.0%) | |
| High | 15 (13.3%) | 10 (10.2%) | 5 (33.3%) | |
| LDH level | 0.024* | |||
| Normal | 69 (61.1%) | 64 (65.3%) | 5 (33.3%) | |
| Elevated | 44 (38.9%) | 34 (34.7%) | 10 (66.7%) | |
| Bone marrow involvement | 0.053 | |||
| Yes | 12 (10.6%) | 8 (8.2%) | 4 (26.7%) | |
| No | 101 (89.4%) | 90 (91.8%) | 11 (73.3%) | |
| Months from diagnosis to ASCT (median, range) | 8 (3–99) | 8 (3–99) | 14 (5–39) | 0.125 |
| Prior regimens | 0.127 | |||
| 78 (69.0%) | 70 (71.4%) | 8 (53.3%) | ||
| 5–10 | 30 (26.5%) | 25 (25.5%) | 5 (33.3%) | |
| ≥10 | 5 (4.4%) | 3 (3.1%) | 2 (13.3%) | |
| Disease status | 0.026* | |||
| CR | 54 (47.8%) | 51 (52.0%) | 3 (20.0%) | |
| PR/NR | 59 (52.2%) | 47 (48.0%) | 12 (80.0%) | |
| Conditioning regimens | 0.054 | |||
| BEAM | 23 (20.4%) | 20 (20.4%) | 3 (20.0%) | |
| BEAC | 31 (27.4%) | 28 (28.6%) | 3 (20.0%) | |
| CBV | 30 (26.5%) | 29 (29.6%) | 1 (6.7%) | |
| CHOP-like | 27 (23.9%) | 20 (20.4%) | 7 (46.7%) | |
| Others | 2 (1.8%) | 1 (1.0%) | 1 (6.7%) | |
| Mononuclear cell dose (×10/kg, median and range) | 5.27 (2.11–15.70) | 5.27 (2.11–15.70) | 5.14 (3.69–7.10) | 0.381 |
| Maintenance therapy | 0.366 | |||
| Yes | 42 (37.2%) | 38 (38.8%) | 4 (26.7%) | |
| No | 71 (62.8%) | 60 (61.2%) | 11 (73.3%) | |
| * ASCT – autologous stem cell transplantation; BEAC – carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM – carmustine, etoposide, cytarabine, and melphalan; BMI – body mass index; CHOP – cyclophosphamide, anthracycline, vincristine, and prednisone; CBV – cyclophosphamide, carmustine, and etoposide; CR – complete remission; ECOG PS – Eastern Cooperative Oncology Group performance status; HL – Hodgkin lymphoma; IPI – international prognostic index; LDH – lactate dehydrogenase; NHL – non-Hodgkin lymphoma; NR – no response; PR – partial remission. | ||||